2025
TP53‐Mutated Acute Myeloid Leukemia and Blast Phase Myeloproliferative Neoplasm: Distinct Mutation Leads to Poorer Prognosis
Chen D, Cantu M, Siddon A, Weinberg O. TP53‐Mutated Acute Myeloid Leukemia and Blast Phase Myeloproliferative Neoplasm: Distinct Mutation Leads to Poorer Prognosis. European Journal Of Haematology 2025, 115: 57-63. PMID: 40152319, PMCID: PMC12134709, DOI: 10.1111/ejh.14421.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaTP53-mutated acute myeloid leukemiaBlast phase myeloproliferative neoplasmsTP53 mutationsClinical outcomesMPN-BPMyeloproliferative neoplasmsMyeloid leukemiaAssociated with prognostic significanceMissense mutationsLow-risk groupSplice site variantOverall survivalAssociated with relatively better prognosisMyeloid neoplasmsPrognostic significanceBetter prognosisTP53 mutantsTherapeutic responseRisk stratificationRetrospective analysisExon 5TP53Exon 6Poorer Prognosis
2023
TP53 mutations and Their Impact on Survival in Patients with Myeloproliferative Neoplasms
Rolles B, De Oliveira Filho C, Keating J, Luskin M, DeAngelo D, Lindsley C, Kim A, Hem J, Kim C, Weeks L, Wazir M, How J, Marneth A, Liu Y, Aryee M, Tsai H, Stahl M, Mullally A. TP53 mutations and Their Impact on Survival in Patients with Myeloproliferative Neoplasms. Blood 2023, 142: 3160. DOI: 10.1182/blood-2023-185024.Peer-Reviewed Original ResearchMyeloproliferative neoplasms diagnosisLoss of heterozygosityVariant allele fractionTP53 mutation detectionSecondary AMLTP53 mutationsMyeloproliferative neoplasm subtypeMyeloproliferative neoplasm patientsMyeloproliferative neoplasmsOverall survivalEssential thrombocythemiaCourse of diseasePolycythemia veraDriver mutationsBlast phase myeloproliferative neoplasmsChronic phase myeloproliferative neoplasmsContext of myeloproliferative neoplasmsMyeloproliferative neoplasm driver mutationsNext-generation sequencingDetect TP53 mutationsDiagnosis to detectionPost-ET/PV myelofibrosisTP53-mutant patientsTP53-mutated patientsMutation detection
2021
Multicenter evaluation of efficacy and toxicity of venetoclax‐based combinations in patients with accelerated and blast phase myeloproliferative neoplasms
King A, Weis T, Derkach A, Ball S, Pandey M, Mauro M, Goldberg A, Stahl M, Famulare C, Tallman M, Wang E, Kuykendall A, Rampal R. Multicenter evaluation of efficacy and toxicity of venetoclax‐based combinations in patients with accelerated and blast phase myeloproliferative neoplasms. American Journal Of Hematology 2021, 97: e7-e10. PMID: 34674293, DOI: 10.1002/ajh.26381.Peer-Reviewed Original ResearchConceptsBlast phase myeloproliferative neoplasmsVenetoclax-based combinationsEvaluation of efficacyMyeloproliferative neoplasmsMulticenter evaluation
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply